Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 769 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hb-SS Disease Clear all
Terminated Phase 1 Interventional

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

NCT02678143
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil, Sirolimus, Fludarabine, Total body irradiation, Hematopoietic stem cell transplant
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 26, 2026, 2:02 PM EDT
Completed No phase listed Observational

A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients

NCT01220115
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
2 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
42
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 26, 2026, 2:02 PM EDT
Completed No phase listed Observational

Pain Management Protocol for Pediatric Sickle Cell Disease

NCT00386048
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Brief Cognitive-Behavioral Pain Management Training
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
8 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

NCT05618301
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Motixafortide, Natalizumab, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 26, 2026, 2:02 PM EDT
Completed No phase listed Observational

Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease

NCT00305175
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload

NCT01039636
View directory record Official record
Conditions
Transfusional Iron Overload, Beta-thalassemia
Interventions
FBS0701
Drug
Lead sponsor
FerroKin BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Oakland, California • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2012 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Not applicable Interventional

The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT

NCT06580067
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Pray Until Something Happens (PUSH), Self-monitoring
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

NCT02187445
View directory record Official record
Conditions
Sickle Cell Disease, Asthma, Acute Chest Syndrome
Interventions
Budesonide inhalation suspension
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Year to 4 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

NCT00029731
View directory record Official record
Conditions
Anemia, Sickle Cell, Pneumonia
Interventions
Arginine hydrochloride
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

NCT02435901
View directory record Official record
Conditions
Sickle Cell Disease, Beta Thalassemia-Major
Interventions
alemtuzumab (Campath IH), Fludarabine, Melphalan, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Hematopoietic Stem Cell Transplantation
Drug · Biological
Lead sponsor
Northwell Health
Other
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Telemedicine for Children With Sickle Cell Disease

NCT05087303
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Types of Telemedicine Delivery Models
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 26, 2026, 2:02 PM EDT
Terminated Phase 2 Interventional

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

NCT00040469
View directory record Official record
Conditions
Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions
Campath -1H, Dilantin, Busulfan, Cyclophosphamide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity

NCT00402480
View directory record Official record
Conditions
Stroke
Interventions
Hydroxyurea
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 26, 2026, 2:02 PM EDT
Not listed No phase listed Observational

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

NCT03535220
View directory record Official record
Conditions
Benign and Malignant Hematologic Diseases
Interventions
Protease Inhibitors
Combination Product
Lead sponsor
American Society of Hematology
Other
Eligibility
1 Year to 65 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 26, 2026, 2:02 PM EDT
Enrolling by invitation No phase listed Observational

Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy

NCT06664541
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 26, 2026, 2:02 PM EDT
Completed No phase listed Observational Results available

Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting

NCT02411396
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Cleveland, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Health Literacy - Neurocognitive Screening in Pediatric SCD

NCT04917783
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Passport Card, No Passport card
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 26, 2026, 2:02 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Hemoglobin SC Disease With Hydroxyurea

NCT02336373
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
hydroxyurea
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 26, 2026, 2:02 PM EDT
Terminated Phase 1 Interventional

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

NCT04091737
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 26, 2026, 2:02 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 26, 2026, 2:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

NCT02447627
View directory record Official record
Conditions
Healthy, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 26, 2026, 2:02 PM EDT
Completed No phase listed Observational

Motivations, Expectations, and Decision-making of Sickle Cell Patients in Clinical Research

NCT03709303
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 26, 2026, 2:02 PM EDT
Active, not recruiting No phase listed Observational

Exploring Adherence Monitoring in Sickle Cell Disease

NCT03708731
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 26, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 26, 2026, 2:02 PM EDT